Literature DB >> 16256874

Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II).

Jagmeet P Singh1, W Jackson Hall, Scott McNitt, Hongyue Wang, James P Daubert, Wojciech Zareba, Jeremy N Ruskin, Arthur J Moss.   

Abstract

OBJECTIVES: The purpose of this study was to prospectively examine the role of clinical, laboratory, echocardiographic, and electrophysiological variables as predictors of appropriate initial implantable cardioverter-defibrillator (ICD) therapy for ventricular tachycardia (VT) or ventricular fibrillation (VF) or death in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II) population.
BACKGROUND: There is limited information regarding the determinants of appropriate ICD therapy in patients with reduced ventricular function after a myocardial infarction.
METHODS: We used secondary analysis in one arm of a multicenter randomized clinical trial in patients with a previous myocardial infarction and reduced left ventricular function.
RESULTS: We analyzed baseline and follow-up data on 719 patients enrolled in the ICD arm of the MADIT-II study. Appropriate ICD therapy was observed in 169 subjects. Clinical, laboratory, echocardiographic, and electrophysiological variables, along with measures of clinical instability such as interim hospitalization for congestive heart failure (IH-CHF) and interim hospitalization for coronary events (IH-CE), were examined with proportional hazards models and Kaplan-Meier time-to-event curves before and after first interim hospitalization. Interim hospitalization-CHF, IH-CE, no beta-blockers, digitalis use, blood urea nitrogen (BUN) >25, body mass index (BMI) > or =30 kg/m2, and New York Heart Association functional class >II were associated with increased risk for appropriate ICD therapy for VT, VF, or death. In a multivariate (stepwise selection) analysis, IH-CHF was associated with an increased risk for the end point of either VT or VF (hazard ratio [HR] 2.52, 95% confidence interval [CI] 1.69 to 3.74, p < 0.001) and for the combined end point of VT, VF, or death (HR 2.97, 95% CI 2.15 to 4.09, p < 0.001). Interim hospitalization-CE was associated with an increased risk for VT, VF, or death (HR 1.66, 95% CI 1.09 to 2.52, p = 0.02).
CONCLUSIONS: These results provide important mechanistic information, suggesting that worsening clinical condition and cardiac instability, as reflected by an IH-CHF or IH-CE, are subsequently associated with a significant increase in the risk for appropriate ICD therapy (for VT/VF) and death.

Entities:  

Mesh:

Year:  2005        PMID: 16256874     DOI: 10.1016/j.jacc.2005.05.088

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  33 in total

1.  Cardiac resynchronization therapy: the MGH experience.

Authors:  Jagmeet P Singh; Jeremy N Ruskin
Journal:  Ann Noninvasive Electrocardiol       Date:  2005-10       Impact factor: 1.468

2.  Cardioverter-defibrillators for primary and secondary prevention in adults with tetralogy of fallot.

Authors:  Elyse Foster
Journal:  Curr Cardiol Rep       Date:  2009-07       Impact factor: 2.931

Review 3.  Sudden cardiac death risk stratification.

Authors:  Marc W Deyell; Andrew D Krahn; Jeffrey J Goldberger
Journal:  Circ Res       Date:  2015-06-05       Impact factor: 17.367

4.  Twenty-five years of implantable defibrillator practice in the USA: are we ready for globalization?

Authors:  Sanjeev Saksena
Journal:  J Interv Card Electrophysiol       Date:  2011-01       Impact factor: 1.900

5.  Prognostic Impact of the Timing of Recurrence of Infarct-Related Ventricular Tachycardia After Catheter Ablation.

Authors:  Konstantinos C Siontis; Hyungjin Myra Kim; William G Stevenson; Akira Fujii; Paolo Della Bella; Pasquale Vergara; Kalyanam Shivkumar; Roderick Tung; Duc H Do; Emile G Daoud; Toshimasa Okabe; Katja Zeppenfeld; Marta de Riva Silva; Gerhard Hindricks; Arash Arya; Alexander Weber; Karl-Heinz Kuck; Andreas Metzner; Shibu Mathew; Johannes Riedl; Miki Yokokawa; Krit Jongnarangsin; Rakesh Latchamsetty; Fred Morady; Frank M Bogun
Journal:  Circ Arrhythm Electrophysiol       Date:  2016-12

6.  High-risk electrocardiographic parameters are ubiquitous in patients with ischemic cardiomyopathy.

Authors:  Mary G Carey; Salah S Al-Zaiti; John M Canty; James A Fallavollita
Journal:  Ann Noninvasive Electrocardiol       Date:  2012-07       Impact factor: 1.468

Review 7.  When Is It Safe Not to Reimplant an Implantable Cardioverter Defibrillator at the Time of Battery Depletion?

Authors:  Sana M Al-Khatib; Daniel J Friedman; Gillian D Sanders
Journal:  Card Electrophysiol Clin       Date:  2018-03

8.  Sudden death after myocardial infarction.

Authors:  A Selcuk Adabag; Terry M Therneau; Bernard J Gersh; Susan A Weston; Véronique L Roger
Journal:  JAMA       Date:  2008-11-05       Impact factor: 56.272

9.  Primary ICD-therapy in patients with advanced heart failure: selection strategies and future trials.

Authors:  Lutz Frankenstein; Christian Zugck; Manfred Nelles; Dieter Schellberg; Andrew Remppis; Hugo Katus
Journal:  Clin Res Cardiol       Date:  2008-03-17       Impact factor: 5.460

10.  Presence of obesity is associated with lower mortality in elderly patients with implantable cardioverter defibrillator.

Authors:  A Jahangir; M Mirza; M Shahreyar; T Mengesha; R Shearer; S Sultan; A Jahangir; I Choudhuri; V Nangia; A Dhala; A Bhatia; I Niazi; J Sra; A J Tajik
Journal:  Int J Obes (Lond)       Date:  2017-08-30       Impact factor: 5.095

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.